Management of Neovascular Age-related Macular Degeneration: Systematic Drug Class Review and Economic Evaluation
In 2006, CADTH commissioned a study of the clinical efficacy and cost-effectiveness of drugs and therapies approved for use in Canada for people with neovascular age-related macular degeneration (AMD). You can view reported findings examining the impact of the pharmaceutical management of AMD in the report below.
This complete report has been extensively peer-reviewed by CADTH staff, and by external clinical and methodological experts.
Management of Neovascular Age-Related Macular Degeneration: Supplemental Analysis
Following the publication of CADTH’s report, additional questions were raised by representatives from provincial and federal public drug plans. CADTH commissioned a supplementary economic evaluation. You can view the latest reported findings in the supplement below.
- Supplement (25 pages)